Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
JAMP filed an application with the Competition Tribunal on July 26, 2024, seeking leave to bring an abuse of dominance case against Janssen relating to ustekinumab (Janssen's STELARA).
JAMP filed an application with the Competition Tribunal on July
26, 2024, seeking leave to bring an abuse of dominance case against
Janssen relating to ustekinumab (Janssen's
STELARA).
JAMP proposes to allege that its ustekinumab biosimilar
(JAMTEKI) business, or alternatively its
biosimilars business, has been significantly harmed by
Janssen's "gaming of the regulatory system and sham
litigation" and other past or ongoing anti-competitive
acts.
The pending decision as to whether JAMP can commence the case
would be the Tribunal's first decision under recent
Competition Act provisions permitting private parties to
apply to bring an abuse of dominance application. Case details are available to view online.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
